From Pfizer Inc. (R.G., D.G., M.W., D.S.R., R.P.B.), Cambridge, UK; Pfizer Inc. (A.O.), Groton, CT; The Epilepsy Study Consortium (B.D.), Reston, VA; Department of Neurology (B.A.-K.), Vanderbilt University Medical Center, Nashville, TN; University of Pennsylvania (M.G., J.P.), Philadelphia; Washington University in St. Louis (R.E.H.), MO; Johns Hopkins Hospital (G.K.), Baltimore, MD; Thomas Jefferson University (M.S.), Philadelphia, PA; Comprehensive Epilepsy Center (B.V., D.F., J.F.), Department of Neurology, New York University, New York; and Consultants in Epilepsy and Neurology PLLC (R.T.W.), Boise, ID. [Email]
The objective of this phase 2a study was to assess the activity of PF-06372865, a positive allosteric modulator (PAM) of α2/3/5 subunit-containing GABAA receptors with minimal activity at α1-containing receptors, which are believed to mediate many of the adverse events associated with benzodiazepines, in the epilepsy photosensitivity model as a proof-of-principle of efficacy.